RCT1100 / ReCode Therap - LARVOL DELTA

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD (clinicaltrials.gov) - P1 | N=7 | Completed | Sponsor: ReCode Therapeutics | Active, not recruiting ➔ Completed | N=10 ➔ 7

Enrollment change • Trial completion • Otorhinolaryngology • Respiratory Diseases

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - P1 | N=9 | Completed | Sponsor: ReCode Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Otorhinolaryngology • Respiratory Diseases

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: ReCode Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Otorhinolaryngology • Respiratory Diseases

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance (clinicaltrials.gov) - P1 | N=12 | Active, not recruiting | Sponsor: ReCode Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Otorhinolaryngology • Respiratory Diseases

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: ReCode Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Otorhinolaryngology • Respiratory Diseases

Study of Inhaled RCT1100 in Adults with Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: ReCode Therapeutics

New P1 trial • Otorhinolaryngology • Respiratory Diseases

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults with PCD (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: ReCode Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Otorhinolaryngology • Respiratory Diseases

A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults with PCD (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: ReCode Therapeutics

New P1 trial • Otorhinolaryngology • Respiratory Diseases

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: ReCode Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Otorhinolaryngology • Respiratory Diseases

ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia (ReCode Press Release) - "ReCode Therapeutics...announced that a patient was treated with RCT1100, a novel mRNA-based therapy currently being evaluated in a Phase 1 study in patients with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene....ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform was used to develop RCT1100, an inhaled mRNA therapy designed to deliver and express DNAI1 mRNA in target cells."

Lipid Nanoparticle • Trial status • Genetic Disorders

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: ReCode Therapeutics | N=32 ➔ 9 | Trial completion date: Dec 2025 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Sep 2024

Enrollment change • Trial completion date • Trial primary completion date • Otorhinolaryngology • Respiratory Diseases

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy Subjects (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: ReCode Therapeutics

New P1 trial • Otorhinolaryngology • Respiratory Diseases

Study Evaluating the Safety and Tolerability of RCT1100 in Healthy Subjects (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: ReCode Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Otorhinolaryngology • Respiratory Diseases